Abstract Background Budget impact analyses (BIAs) are an essential part of a
comprehensive economic assessment of a health care intervention and are increasingly …

This evaluation determines whether published studies to date meet the key characteristics
identified for budget impact analyses (BIA) for medicines, accomplished through a …

This article reviews budget-impact analyses (BIAs) published to date in peer-reviewed bio-
medical journals with reference to current best practice, and discusses where future …

Purpose To evaluate the cost-effectiveness of 12-month adjuvant trastuzumab therapy in
women with high-risk human epidermal growth factor receptor 2 (HER2)–positive early …

Purpose The aim of this study was to evaluate the cost-effectiveness of ribociclib compared
to palbociclib, both in combination with letrozole, in the first-line treatment of …

OBJECTIVE: Breast cancer, the most common malignant cancer among women in Western
countries, has poor prognosis following metastasis. New therapies potentially extend …

To determine whether authors conducting economic analyses of aromatase inhibitors in
breast cancer are less likely to reach unfavorable conclusions if the economic study is …

The purpose of this study was to estimate in all randomised trials the relative risk of overall
response rate (ORR), clinical benefit (CB), time to progression (TTP), overall survival (OS) …

Objective. To examine the impact of structural uncertainty of Markov models in modeling cost-
effectiveness for the treatment of advanced breast cancer (ABC). Methods. Four common …

Background Breast cancer (BC) is the most common cancer globally among women, with
2,261,419 new cases in 2020; systemic treatment may be neo-adjuvant, adjuvant, or both …